140 related articles for article (PubMed ID: 18071336)
1. Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor.
Morrison J; Briggs SS; Green N; Fisher K; Subr V; Ulbrich K; Kehoe S; Seymour LW
Mol Ther; 2008 Feb; 16(2):244-51. PubMed ID: 18071336
[TBL] [Abstract][Full Text] [Related]
2. Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer.
Green NK; Morrison J; Hale S; Briggs SS; Stevenson M; Subr V; Ulbrich K; Chandler L; Mautner V; Seymour LW; Fisher KD
J Gene Med; 2008 Mar; 10(3):280-9. PubMed ID: 18214996
[TBL] [Abstract][Full Text] [Related]
3. Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer.
Morrison J; Briggs SS; Green NK; Thoma C; Fisher KD; Kehoe S; Seymour LW
Hum Gene Ther; 2009 Mar; 20(3):239-51. PubMed ID: 19257852
[TBL] [Abstract][Full Text] [Related]
4. PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer.
Kloos A; Woller N; Gürlevik E; Ureche CI; Niemann J; Armbrecht N; Martin NT; Geffers R; Manns MP; Gerardy-Schahn R; Kühnel F
Cancer Immunol Res; 2015 Jul; 3(7):751-63. PubMed ID: 25701327
[TBL] [Abstract][Full Text] [Related]
5. Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.
Pereboeva L; Komarova S; Roth J; Ponnazhagan S; Curiel DT
Gene Ther; 2007 Apr; 14(8):627-37. PubMed ID: 17251987
[TBL] [Abstract][Full Text] [Related]
6. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM
Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768
[TBL] [Abstract][Full Text] [Related]
7. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies.
Fisher KD; Stallwood Y; Green NK; Ulbrich K; Mautner V; Seymour LW
Gene Ther; 2001 Mar; 8(5):341-8. PubMed ID: 11313809
[TBL] [Abstract][Full Text] [Related]
8. Systemic image-guided liver cancer radiovirotherapy using dendrimer-coated adenovirus encoding the sodium iodide symporter as theranostic gene.
Grünwald GK; Vetter A; Klutz K; Willhauck MJ; Schwenk N; Senekowitsch-Schmidtke R; Schwaiger M; Zach C; Wagner E; Göke B; Holm PS; Ogris M; Spitzweg C
J Nucl Med; 2013 Aug; 54(8):1450-7. PubMed ID: 23843567
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor-2-retargeted adenoviral vector for selective transduction of primary glioblastoma multiforme endothelial cells.
Gupta V; Wang W; Sosnowski BA; Hofman FM; Chen TC
Neurosurg Focus; 2006 Apr; 20(4):E26. PubMed ID: 16709032
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins.
Stevenson M; Hale AB; Hale SJ; Green NK; Black G; Fisher KD; Ulbrich K; Fabra A; Seymour LW
Cancer Gene Ther; 2007 Apr; 14(4):335-45. PubMed ID: 17235355
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob.
Nishimoto T; Yoshida K; Miura Y; Kobayashi A; Hara H; Ohnami S; Kurisu K; Yoshida T; Aoki K
Gene Ther; 2009 May; 16(5):669-80. PubMed ID: 19225547
[TBL] [Abstract][Full Text] [Related]
12. Preparation of a novel adenovirus formulation with artificial envelope of multilayer polymer-coatings: therapeutic effect on metastatic ovarian cancer.
Yoshihara C; Hamada K; Koyama Y
Oncol Rep; 2010 Mar; 23(3):733-8. PubMed ID: 20127013
[TBL] [Abstract][Full Text] [Related]
13. Suppression of ovarian cancer growth via systemic administration with liposome-encapsulated adenovirus-encoding endostatin.
Yang L; Wang L; Su XQ; Wang L; Chen XC; Li D; Luo ST; Shi HS; Chen LJ; Wang YS
Cancer Gene Ther; 2010 Jan; 17(1):49-57. PubMed ID: 19609295
[TBL] [Abstract][Full Text] [Related]
14. A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy.
Hakkarainen T; Hemminki A; Curiel DT; Wahlfors J
Int J Mol Med; 2006 Oct; 18(4):751-9. PubMed ID: 16964432
[TBL] [Abstract][Full Text] [Related]
15. In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery.
Coughlan L; Vallath S; Saha A; Flak M; McNeish IA; Vassaux G; Marshall JF; Hart IR; Thomas GJ
J Virol; 2009 Jul; 83(13):6416-28. PubMed ID: 19369326
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of a systemically delivered oncolytic adenovirus - biodegradable polymer complex.
Kim J; Li Y; Kim SW; Lee DS; Yun CO
Biomaterials; 2013 Jun; 34(19):4622-31. PubMed ID: 23541109
[TBL] [Abstract][Full Text] [Related]
17. Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.
Nanni P; Gatta V; Menotti L; De Giovanni C; Ianzano M; Palladini A; Grosso V; Dall'ora M; Croci S; Nicoletti G; Landuzzi L; Iezzi M; Campadelli-Fiume G; Lollini PL
PLoS Pathog; 2013 Jan; 9(1):e1003155. PubMed ID: 23382683
[TBL] [Abstract][Full Text] [Related]
18. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT
Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792
[TBL] [Abstract][Full Text] [Related]
19. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
20. Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.
Coughlan L; Vallath S; Gros A; Giménez-Alejandre M; Van Rooijen N; Thomas GJ; Baker AH; Cascalló M; Alemany R; Hart IR
Hum Gene Ther; 2012 Sep; 23(9):960-79. PubMed ID: 22708837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
